Before any new treatment can be approved, it must first go through a prescribed series of clinical trials to assess first its safety and then its efficacy.
The mutually beneficial relationship between patients and research at the Anne Rowling Clinic provides an ideal platform to conduct clinical trials.
Please note that participation in any trial is entirely voluntary.
Clinical Trials Enrolling Now
- Effect of MD1003 (high dose Biotin) in progressive MS: a randomised double blind placebo controlled study
The "Biotin Study" is a randomised double blind placebo controlled study. The purpose of this clinical research study is to look at the effect and safety of MD1003 (high dose Biotin) in participants with progressive MS.
For more information, see MedDay.pharma.com
ClinicalTrials.gov Identifier: NCT02936037
Read more in our neews article (18th August 2017)
- RESTART - REstart or STop Antithrombotics Randomised Trial
RESTART is a randomised controlled trial for adults surviving spontaneous intracerebral haemorrhage who had taken an antithrombotic drug (i.e. anticoagulant or antiplatelet medication) for the prevention of vaso-occlusive disease before the haemorrhage.
For more information see www.restarttrial.org/default.html.
- Multiple Sclerosis - Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART)
This trial, run jointly with University College London, will assess the effect of three drugs (ibudilast, riluzole and amiloride) versus placebo in secondary progressive MS. THIS TRIAL IS NOW FULLY ENROLLED.
ClinicalTrials.gov Identifier: NCT01910259
For more details, see www.ms-smart.org
Read more in our news article (1st April 2015): New clinical trial in multiple sclerosis
Fully Enrolled Clinical Trials / Recent Clinical Trials
This study is investigating whether treatment with a drug called Natalizumab (Tysabri) slows down the accumulation of disability in people with secondary progressive MS. THIS STUDY IS FULLY ENROLLED.
ClinicalTrials.gov Identifier: NCT01416181
This three-year study will try to determine if a drug called Daclizumab is more effective in the treatment of MS than a currently available treatment. It also aims to provide researchers with more information about the safety of the long-term treatment with the drug in people with MS. THIS STUDY IS FULLY ENROLLED.
ClinicalTrials.gov Identifier: NCT01064401